Pheromone Sciences

Pheromone Sciences was a Canadian biotechnology company that developed non-invasive medical devices for monitoring women's reproductive health. The company's core technology was a wearable biosensor, marketed as the OV-Watch, which predicted ovulation by detecting the 'chloride surge' in a woman's perspiration. This surge typically occurs several days before ovulation, providing a wider fertile window than traditional luteinizing hormone tests. Headquartered in Toronto, the company was publicly traded on the TSX Venture Exchange under the symbol PHS. In 2003, Pheromone Sciences was acquired by SeraCare Life Sciences for approximately $2.5 million. The acquisition allowed SeraCare to expand its diagnostic and monitoring product offerings in the women's health sector.